NCCN recently modified their guidelines in 2024 so that a family history of PC is no longer required for those with an ATM or BRCA2 PGV, though NCCN does note that a first or second degree relative (from the same side of the family as the PGV) must be affected with PC in order for those with a BRCA1 or PALB2 PGV to qualify for surveillance [12]. This evidence concerns the gene PALB2 and pachyonychia congenita.